Sinjard-L 10 mg+5 mg (Tablet)

Unit Price: ৳ 30.00 (4 x 7: ৳ 840.00)
Strip Price: ৳ 210.00

Medicine Details

Category Details
Generic Empagliflozin linagliptin
Company Beacon pharmaceuticals plc
Also available as
Sinjard l 25 mg tablet

Indications

  • Adjunct to diet and exercise
  • Improves glycemic control
  • Type 2 diabetes mellitus

Pharmacology

  • Inhibits DPP-4 enzyme
  • Increases active incretin hormones
  • Stimulates insulin release
  • Decreases glucagon levels
  • Reduces hepatic glucose output
  • Reduces renal reabsorption of glucose

Dosage & Administration

  • Recommended daily dose: 10 mg Empagliflozin and 5 mg Linagliptin
  • Taken in the morning
  • With or without food
  • Increased dose to 25 mg Empagliflozin and 5 mg Linagliptin once daily
  • Assess renal function before initiating

Interaction

  • Diuretics increase urine volume and frequency of voids
  • Insulin or Insulin Secretagogues increases risk for hypoglycemia
  • Rifampin decreases Linagliptin exposure
  • SGLT2 inhibitors lead to positive urine glucose tests

Contraindications

  • Severe renal impairment
  • End-stage renal disease
  • Dialysis
  • Hypersensitivity reaction to Linagliptin or Empagliflozin

Side Effects

  • Pancreatitis
  • Ketoacidosis
  • Volume Depletion
  • Urosepsis and Pyelonephritis
  • Hypoglycemia
  • Necrotizing Fasciitis
  • Genital Mycotic Infections
  • Hypersensitivity Reactions
  • Severe Arthralgia
  • Bullous Pemphigoid
  • Heart Failure

Pregnancy & Lactation

  • Not recommended during second and third trimesters
  • Limited data in pregnant women
  • Risks associated with poorly controlled diabetes in pregnancy

Precautions & Warnings

  • Precautions in Pancreatitis, Hypotension, Ketoacidosis, Acute Kidney Injury, Urosepsis, Hypoglycemia, Genital Mycotic Infections, Hypersensitivity
  • Reports of serious adverse reactions such as pancreatitis and ketoacidosis
  • Association with heart failure observed in cardiovascular outcomes trials

Overdose Effects

  • Contact Poison Control Center in case of overdose
  • Supportive measures required
  • Removal of Empagliflozin by hemodialysis not studied
  • Removal of Linagliptin by hemodialysis or peritoneal dialysis unlikely

Therapeutic Class

  • Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

Storage Conditions

  • Store below 30°C
  • Keep away from light and wet place
  • Keep out of reach of children

Related Brands